CD274 CD274 molecule
ENSG00000120217 · protein coding · Open Targets profile
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:32929201). {ECO:0000269|PubMed:10581077, ECO:0000269|PubMed:11015443, ECO:0000269|PubMed:28813410, ECO:0000269|PubMed:28813417, ECO:0000269|PubMed:31399419, ECO:0000269|PubMed:32929201, ECO:0000269|PubMed:36727298}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, High-Quality Ligand, Med-Quality Pocket
- Antibody
- Approved Drug, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Literature, UniProt Ubiquitination, Small Molecule Binder
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 0.2659600079059601 (upper bound 0.4798800051212311). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 400 registry trials, updated in the last three years, of the most advanced drugs against CD274 (sugemalimab, avelumab, cosibelimab, atezolizumab, durvalumab, envafolimab, bintrafusp alfa, adebrelimab, socazolimab, erfonrilimab, danburstotug, pacmilimab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Evanthia GalanisAlliance Foundation Trials, LLC. · 3 of 3 trials Phase 2+
- Samuel FuntMemorial Sloan Kettering Cancer Center · 3 of 3 trials Phase 2+Ph1/Ph2NCT02989584 · A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancerbrief
- Andrea B ApoloNational Cancer Institute (NCI) · 2 of 3 trials Phase 2+Ph2NCT06161532 · Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...brief
- A P ChenNational Cancer Institute LAO · 2 of 2 trials Phase 2+
- Arun RajanNational Cancer Institute (NCI) · 2 of 2 trials Phase 2+
- Filippo PietrantonioFondazione IRCCS - Istituto Nazionale dei Tumori di Milano · 2 of 2 trials Phase 2+
- John WalkerAlberta Health services · 2 of 2 trials Phase 2+
- Linda MartinUniversity of Virginia · 2 of 2 trials Phase 2+
- Myriam ChalabiAntoni van Leeuwenhoek · 2 of 2 trials Phase 2+
- Narek ShaverdianMemorial Sloan Kettering Cancer Center · 2 of 2 trials Phase 2+
- Thomas LycanWake Forest University Health Sciences · 2 of 2 trials Phase 2+
- William E GillandersYale University Cancer Center LAO · 2 of 2 trials Phase 2+
- Dwight H OwenECOG-ACRIN Cancer Research Group · 1 of 2 trials Phase 2+
- Eliza HawkesAustin Health · 1 of 2 trials Phase 2+
- Thomas PowlesQueen Mary University of London · 1 of 2 trials Phase 2+
Registry trials of sugemalimab, avelumab, cosibelimab, atezolizumab, durvalumab, envafolimab, bintrafusp alfa, adebrelimab, socazolimab, erfonrilimab, danburstotug, pacmilimab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 259 of 385 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 15 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
415 trials of drugs against CD274 were stopped early; 1 of the 200 most recent give no reason
Terminated, withdrawn and suspended interventional trials of sugemalimab, avelumab, cosibelimab, atezolizumab, durvalumab, envafolimab, bintrafusp alfa, adebrelimab, socazolimab, erfonrilimab, danburstotug, pacmilimab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 415.
- suspended · 2026-11-10 · National Cancer Institute (NCI) · durvalumab“Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.”
- terminated · 2026-11-10 · William Zeitler · Durvalumab“funding change”
- terminated · 2026-11-05 · University of Maryland, Baltimore · matched by the registry's drug synonyms“Limited Accrual”
- terminated · 2026-11-04 · AHS Cancer Control Alberta · Avelumab and Radical radiotherapy“Loss of Pharma Support”
- suspended · 2026-11-02 · National Cancer Institute (NCI) · Atezolizumab“Other - Assessing accrual feasibility”
- suspended · 2026-10-29 · National Cancer Institute (NCI) · Atezolizumab“Scheduled Interim Monitoring”
- terminated · 2026-10-20 · National Cancer Institute (NCI) · Atezolizumab“The study was terminated due to a shortage of the drug supply.”
- terminated · 2026-10-01 · Coherus Oncology, Inc. · Atezolizumab“Sponsor decision”
- terminated · 2026-09-22 · National Cancer Institute (NCI) · Durvalumab“Closed due to slow accrual.”
- suspended · 2026-09-18 · Dwight Owen · Atezolizumab“Pending ICF update”
- terminated · 2026-09-15 · Hoffmann-La Roche · Atezolizumab“Study was closed early as the sponsor decided not to continue development of certain treatment combinations.”
- suspended · 2026-09-14 · University of Maryland, Baltimore · Durvalumab 50 MG/1 ML Intravenous Solution“PI changed institution. Not yet approved at current location.”
- suspended · 2026-09-04 · National Cancer Institute (NCI) · Durvalumab“Other - evaluation of patients on first stage”
- terminated · 2026-09-02 · Memorial Sloan Kettering Cancer Center · Durvalumab“Study closed by Amgen due to lack of enrollment”
- terminated · 2026-08-04 · Academic and Community Cancer Research United · matched by the registry's drug synonyms“Sponsor has withdrawn support for the study.”
- terminated · 2026-08-03 · Hoffmann-La Roche · Atezolizumab“The study was closed because the sponsor decided not to continue the development of certain treatment combinations.”
- terminated · 2026-08-03 · Hoffmann-La Roche · Atezolizumab“Study was closed early as the sponsor decided not to continue development of certain treatment combinations.”
- withdrawn · 2026-08-03 · University of Utah · Durvalumab“Slow accrual”
- terminated · 2026-07-29 · EMD Serono Research & Development Institute, Inc. · Avelumab“The study was stopped due to a lack of clear evidence of anti-tumor activity with the combination treatment in the participants treated.”
- terminated · 2026-07-22 · University of Utah · Durvalumab“Closed due to slow accrual”
- terminated · 2026-07-16 · Jonsson Comprehensive Cancer Center · Durvalumab (MEDI 4736)“Low accrual”
- terminated · 2026-07-16 · Dana-Farber Cancer Institute · Durvalumab“Criteria not met for second stage at time of interim analysis”
- terminated · 2026-07-08 · Gustave Roussy, Cancer Campus, Grand Paris · matched by the registry's drug synonyms“Toxicities”
- terminated · 2026-06-29 · University Health Network, Toronto · Durvalumab“Study Terminated Prior to trial activation, due to changes in SOC of the treatment”
- terminated · 2026-06-18 · University of Texas Southwestern Medical Center · Atezolizumab and bevacizumab“The decision was made to close the study to enrollment due to poor overall accrual and the inability to meet the 31% overall enrollment goal.”
Paediatric incentives and obligations for CD274's drugs
For sugemalimab, avelumab, cosibelimab, atezolizumab, durvalumab, envafolimab, bintrafusp alfa, adebrelimab, socazolimab, erfonrilimab, danburstotug, pacmilimab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: yes · CD274 is on the list. Membership alone neither requires nor waives a pediatric study.Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-001849-PIP02-15-M05 (avelumab, Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms);Treatment of malignant neoplasms of lymphoid tissue;Treatment of malignant neoplasms of the central nervous system): PM: decision on the application for modification of an agreed PIP, 22 Aug 2024; EMEA-003418-PIP01-23 (tiragolumab;atezolizumab, Treatment of lung carcinoma): W: decision granting a waiver in all age groups for all conditions or indications, 8 Aug 2023; EMEA-002028-PIP01-16-M04 (durvalumab, Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue);Treatment of malignant neoplasms of lymphoid tissue): PM: decision on the application for modification of an agreed PIP, 11 Aug 2023; EMEA-003179-PIP01-22 (sugemalimab, Treatment of lung cancer): W: decision granting a waiver in all age groups for all conditions or indications, 10 Jun 2022; +4 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/15/1590 withdrawn 14 Dec 2015: Treatment of Merkel cell carcinoma; EU/3/16/1798 withdrawn 12 Dec 2016: Treatment of gastric cancerRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Imfinzi: authorised since 21 Sept 2018; Bavencio: authorised since 18 Sept 2017; Cejemly: authorised since 24 Jul 2024; Tecentriq: authorised since 20 Sept 2017Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: yes · Avelumab [Bavencio], 23 Mar 2017: Treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC); Atezolizumab and hyaluronidase-tqjs [Tecentriq Hybreza], 24 Nov 2025: Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic alveolar soft part sarcoma (ASPS); Atezolizumab [Tecentriq], 9 Dec 2022: As a single agent, for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS)Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 49 interventional studies of sugemalimab, avelumab, cosibelimab, atezolizumab, durvalumab, envafolimab, bintrafusp alfa, adebrelimab, socazolimab, erfonrilimab, danburstotug, pacmilimab include patients under 18; 30 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 13 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.